October 8, 2013 — The World Molecular Imaging Society (WMIS) held its sixth annual congress in Savannah, Ga. Sept. 18-21. The World Molecular Imaging Congress (WMIC) 2013 featured advancements in molecular multimodal imaging with a focus on discovery, pre-clinical and translational research, highlighting first-in-human studies that drive innovative diagnostics and targeted therapy critical to the implementation of precision medicine.
“Molecular imaging and targeted therapy are essential to the successful implementation of precision medicine,” said Hedvig Hricak M.D., Ph.D., chairman, radiology; Memorial Sloan-Kettering Cancer Center and one of eight plenary speakers at the WMIC 2013. “The WMIC is a unique international forum for discussing all aspects of molecular imaging research, from an idea to preclinical studies to first-in-human imaging trials. The WMIS is taking the lead in the global discussions of MI and its clinical applications and it is a pleasure and honor to take part in the 2013 WMIS annual meeting."
The program consisted of 168 oral presentations and 35 spotlight presentations emphasizing five categories: Chemistry and Imaging Probes, First-in-Human and Clinical Studies, Preclinical Cell and Tissue Level Studies, Preclinical In Vivo Studies and Technology and Software development.
For more information: www.wmicmeeting.org